Adverse drug reactions have been linked with HLA alleles in different studies. These HLA proteins 8 play an essential role in the adaptive immune response for the presentation of self and non-self 9 peptides. Anti-thyroid drugs methimazole and propylthiouracil have been associated with drug 10 induced agranulocytosis (severe lower white blood cell count) in patients with B*27:05, B*38:02 and 11 DRB1*08:03 alleles in different populations: Taiwanese, Vietnamese, Han Chinese and Caucasian. 12
Introduction 27
Adverse drug reactions have been linked to Human Leukocyte Antigens (HLA) in multiple different 28 studies, where an individual carrying a specific risk allele has a higher risk of developing a reaction to 29 that drug, including skin conditions like Stevens-Johnson syndrome and toxic epidermal necrolysis 30 (SJS/TEN) and drug induced liver injury (1-3). HLA proteins play a role in the adaptive immune 31 response, presenting peptides to the T-cell receptors. Non-self peptides are then recognised and 32 elicit an immune response where appropriate (4). Occasionally, unnatural interaction of drugs during 33 this process results in an adverse drug reaction. The role of HLA in these adverse drug reactions has 34 been hypothesised in three main ways: the Hapten model, the Pharmacological Interaction model 35 and the Altered Peptide Repertoire model. The Hapten model predicts the drug binds covalently to a 36 self-protein and is processed via HLA molecules; this drug-protein combination is presented and 37 recognised as being non-self, initiating an immune response (5). The Pharmacological Interaction (PI) 38 model predicts the drugs bind directly to the TCR or via the formation of HLA-drug complexes which 39 activate T cells and thus initiate an immune response without the need for a specific peptide ligand 40 (6) . Except where noted below, the results presented here work under the assumption that the 41 drugs we are investigating here will follow the Altered Peptide Repertoire model, with the drug 42 interacting non-covalently with the HLA molecule directly within the antigen presentation site. This 43 leads to a difference in the self-peptide set that is presented to the T-cell receptors and thus, 44 initiating an immune response (7) . Currently, the most widely investigated HLA-ADR association is 45 the Altered Peptide Repertoire model with high confidence for abacavir, including the crystal 48 structure for abacavir bound in the peptide binding groove of the associated risk allele, B*57:01, 49 along with proteomics evidence for different peptides being presented in the bound and unbound 50 cases (8) . 51
The peptide binding groove of the HLA is a long hydrophobic cleft formed between the α-helices and 52 β-sheet platform. This cleft is much larger than the naturally involved binding sites that proteins 53 have for small organic molecules. The peptide binging groove contains six subsites (S4 Fig). The size 54 and stereochemistry of the subsites are determined by the polymorphic residues along the cleft (10). 55
The specificity of peptide binding is determined, in part, by the interactions between anchor 56 residues on the peptide side chains at two or more of these subsites (11) . 57
Anti-thyroid drugs are used to treat hyperthyroidism as they normalise thyroid function through 58 binding to the thyroid peroxidase enzyme (12). These drugs are thioamides containing a 59 thiocarbonyl group and a thiourea moiety within a heterocyclic structure. The common agents used 60 are methimazole, carbimazole and propylthiouracil (13) . Agranulocytosis has been defined as 61 absolute neutrophil count below 500/µl of blood and includes not only neutrophil count but also the 62 absolute number of eosinophils, basophils and mast cells (14) . Patients with severe neutropenia are 63 likely to experience infections which may be life-threatening or even fatal. The mechanism of anti-64 thyroid induced agranulocytosis is through either direct toxicity or immune-mediated toxicity (14) . 65
The incidence of agranulocytosis in England and Wales has been estimated at around 7 cases per 66 million people per year, with an adjusted odds ratio for neutropenia of 34.7 for users of thyroid 67 inhibitors (i.e. anti-thyroid drugs) (15). Most cases of agranulocytosis are idiosyncratic reactions to 68 drugs or their metabolites, including anti-thyroid drugs. Other causes include splenic sequestration, 69 nutritional deficiencies, infections, immune neutropenia, haematological disease and primary 70 congenital or chronic neutropenia (16) . An increased risk of agranulocytosis has been associated 71 with anti-thyroid drugs carbimazole, methimazole and propylthiouracil for three different HLA alleles 72 in Asian and Caucasian populations, these associations are shown in Table 1 . 73 two associated drugs share a common thiocarbonyl group, which is also seen in the experimental 77 anti-thyroid drugs. The associated anti-thyroid drugs share a common target, thyroid peroxidase, in 78 their normal mechanism of action (21). A study by Pradhan et al. conducted molecular docking of 79 methimazole and propylthiouracil with thyroid peroxidase. The results of this study predicted both 80 drugs to bind in the same position, with the sulphur group forming a hydrogen bond with Arg491 of 81 the thyroid peroxidase, resulting in inhibition of thyroid hormone production (12). As these drugs 82
show similar binding to the same target, it is reasonable to hypothesise that both drugs might also 83 have a shared mechanism for the adverse drug reaction, going some way to explaining why multiple 84 drugs have been associated with the same alleles. It can be noted that methimazole is more 85 commonly associated than propylthiouracil, although neither drug has been studied in isolation (17, 86 18, 20) . In the He et al. study, there were 26 methimazole agranulocytosis cases compared to 3 for  87 propylthiouracil. For the Chen et al. study, of the 42 thioamide-induced agranulocytosis cases, it was 88 stated that 9 of these were patients taking carbimazole, 9 propylthiouracil and 23 methimazole. For 89 the Hallberg et al. study, 39 cases were induced by anti-thyroid agents, of these 29 were 90 methimazole, 5 carbimazole and 5 propylthiouracil. Although all three anti-thyroid drugs have been 91 incorporated into the association studies, our study focuses on the associations seen with 92 methimazole and propylthiouracil. Carbimazole is the pro-drug of methimazole, responsible for the 93 antithyroid activity, and has a short half-life of 5.3-5.4 hours with peak plasma concentrations of 94 methimazole being present after 1 or 2 hours (22, 23) . We are working under the assumption that 95 the mechanisms involved in the adverse drug reaction follow the altered peptide repertoire model, 96 the active drug methimazole would be most likely to interact with the HLA during this process and so 97 carbimazole is excluded from this analysis. 98 B*38:02 has a very similar sequence to B*38:01 with only one residue difference (B*38:02 Thr80Ile 99 B*38:01). It therefore is highly possible that B*38:01 could also be a risk allele in this context. populations. Due to the differences in general structure between Class I and Class II HLA, it is difficult 120 to compare docking predictions between the two allele classes. The B*38:02 and B*38:01 alleles 121 were modelled using the same template structures, with the DRB1*08:03 structure modelled using 122 only DRB1*01:01 as a template. The quality of the models used for molecular docking can impact the 123 docking results and therefore the selection of templates is very important. 124
The purpose of this study is to investigate the associated alleles, in particular looking for 125 commonalities between the two associated HLA-B alleles in order to look for similarities in these 126 alleles that might shed light on the underlying mechanisms of the adverse drug reactions seen. 127
Methods

128
Sequence and structural analysis 129 In order to conduct a reliable analysis between cases and controls, the control alleles must first be 130 carefully selected to ensure they can be reliably assumed to be non-associated. The case and control 131 frequencies from He et al. (17) , Chen et al. (18) and Hallberg et al. (20) were compared alongside 132 healthy individual frequency data obtained from AFND (24). Alleles where the study control allele 133 frequency or healthy individual frequencies sourced from AFND were similar to or greater than the 134 case allele frequencies were selected as controls (Supplementary material i). These alleles could 135 safely be assumed to be non-associated as they do not show enrichment in the case groups. 136
Structural differences were assessed between the risk and selected control alleles. Firstly, the 137 peptide binding regions were compared, this is likely where the drug binding would occur and so 138 differences here would be important for the mechanism of interaction involved in the adverse drug 139 reaction. The peptide binding regions were compared using MHC motif viewer (25) NetMHCpan scores to give predictions of motifs or similarities between peptides. NetMHCpan uses 145 artificial neural networks to predict the peptide binding of HLA molecules based on IEDB 146 experimental data of peptides known to be presented by given alleles, including data for the binding 147 of peptides to B*27:05 and B*38:01 (27, 28) . Therefore, the predictions generated will be based 148 largely on experimental data. 149
The protein molecules were further compared using multiple sequence alignment to view 150 differences across the whole protein and also individual residue changes within sub-pockets along 151 the peptide binding groove between the risk and control alleles. Firstly, the sequences for the risk, 152 possible risk and control alleles were aligned. The alignments were then extended to look at 153 common alleles selected from AFND and NMDP (National Marrow Donor Program) (20, 24) Asian 154 and Caucasian populations and extended further again to consider common alleles found in all 155 populations. When considering the common alleles, it is important to note that the definitive risk 156 profile (association status) of these alleles is unknown. Although, due to the high frequency and the 157 fact that they have not been seen to be associated with agranulocytosis, it can be assumed that 158 these alleles are likely not associated. These multiple sequence alignments allow us to look for 159 residue similarities unique to the risk alleles and therefore identify residues which may be involved 160 in the mechanism of binding for the adverse drug reactions. 161
Molecular Docking
162
Molecular docking was used to compare the predicted binding sites between risk and control alleles. 163
Crystal structures were obtained from the PDB database where available. For those alleles where the 164 crystal structures are not available, the structures were predicted using Modeller (29, 30) . Crystal 165 structures, given the suffix '_S', were available for B*27:05 (1OGT (31)), B*15:01 (1XR9 (32)) and 166 B*51:01 (1E27 (33)). Homology models, given the suffix '_M', were created for B*38:02, B*38:01, 167 B*40:06, B*46:01 and B*54:01 (S1 Table) . Structures and sequences of three similar alleles were obtained searching the PDB database using 172 BLAST-P (34). The structures for these similar alleles, with high sequence identity (e.g. 95-98% 173 identity for the B*38:02 templates), were then used as templates for Modeller. Target and template 174 sequences were aligned with ClustalX (35) and ten models were made for each structure, using 175 Modeller 9.9 automodel class (36). The model with the lowest objective function was chosen for the 176 docking. S1 Table summarises the files were prepared using AutoDock Tools (40) for both the alleles and drug structures. AutoGrid (41) 182 was used to map the target allele structures and select grid points in order to search both the 183 peptide binding groove (PBG) and the top three largest pockets (Top3). The top three largest pockets 184 were selected by pocket volume. Searching the largest pockets on the protein increases the search 185 space to cover more of the protein and allows an alternate binding position away from the peptide 186 binding region. This helps identify if the peptide binding groove is in fact the most favourable binding 
Results
208
Sequence and Structural Analysis
209
We firstly investigated whether allele frequencies for controls were representative of larger 210 populations available in similar regions. This allows us to test for potential biased sampling in source 211 studies, especially as controls have been combined from different countries, as well as to determine 212 our own control (non-associated) alleles for further comparison. Case and control frequencies were 213 calculated from the data provided for the He et al. and Hallberg et al. studies (17, 20) . Alleles with 214 study control frequency over 3% were investigated. Five alleles were selected to be used as controls: The MHC Motif viewer (25) displays the preference for given HLA alleles to bind peptides with amino 220 acids at given positions within an n-mer peptide e.g. 9mer for HLA class I. The motifs have been 221 generated via the NetMHCpan (27) prediction method being run over a large selection of natural 222 peptides, which has been trained originally with experimental data (peptides presented by given HLA 223 alleles) from the IEDB database (28). While the predicted motifs cannot give us a direct measure of 224 the likelihood of a drug to bind in the cleft of a given HLA allele, they can be indicative of whether 225 different alleles share similar peptide binding regions. If the hapten hypothesis of HLA-mediated 226
ADRs was true for anti-thyroid drugs, then the peptide binding ability of associated alleles might be 227 controls, it can be seen that there are two residues which are seen to be unique to the risk alleles: 252
Cys67 and Thr80 (Fig 2) . These are both residues that were identified as potentially important in the 253 Chen et al. study (18) . When the comparisons were extended to look at common alleles, obtained 254 from searching AFND for Caucasian and Asian populations and also common alleles found in the 255 NMDP database (20) (S10 Fig) , a similar pattern can be seen. These two residues are rarely found in 256 these common alleles, although it must be noted that the association status of these common alleles 257 is unknown. 258 similarity between these alleles, it may be that these alleles show similar binding due to the 300 similarity of the modelled structures. Two alleles that differ little will often show similar models, 301 although larger differences would likely have an effect. These models were shown to be structurally 302 similar with an RMSD of 0.460Å (221 to 221 atoms). groove, when expanding the analysis to 100 runs. From this we can see consistent favouring of the F 341 pocket for the risk alleles. Although the docking is not able to fully distinguish between the risk and 342 controls, with the controls showing mixed favouring of the B and F pockets, it is evident that docking 343 against the risk alleles strongly favours binding in the F pocket for each of the drugs. 344 Table 4 summarises the number of poses making hydrophobic interactions with position Thr80 of 364 both risk alleles for each of the investigated drugs. It can be seen that for B*27:05 the associated 365 drugs often make Thr80 interactions with interactions with the thiocarbonyl group being most 366 favourable. The experimental drugs show similar interactions with Thr80 as those seen with the 367 associated drugs (S14 Fig). For B*38:02, fewer interactions are made between the drugs and the 368 position 80 Thr residue than seen for B*27:05 (S15 Fig). In both risk alleles, the most favourable 369 poses commonly form interactions between the thiocarbonyl group of methimazole, 370
propylthiouracil, MZY and TUL, and positions 77, 80, 81, 84 and 123. Interactions are also seen with 371 positions 95, 116, 124, 143 and 147. All these residues seen making interactions surround the F-372 pocket. Positions 77, 80 and 123 were identified as of interest by the Chen et al. study (18) . This adds 373 strength to the hypothesis that the Thr80 position could be involved in the mechanism here, 374 especially for B*27:05. The structure of the ligands, mainly the 'S' group found in the associated and 375 experimental anti-thyroid drugs, could therefore be potentially important for the predicted binding 376 poses seen here. 377 Summary counts showing the number of poses seen making interactions with the Thr80 residue of 379 each of the associated risk alleles for the associated drugs (MMZ and PTU) , the experimental anti-380 thyroid drugs containing the thiocarbonyl group (MZY and TUL) and the other investigated ligands. 381
Where 'No Thr 80' relates to poses showing no interactions between the Thr80 residue and the drug, interactions made between Thr80 and the drug but not with the thiocarbonyl group. The 'Most 384 favourable pose' column shows the interaction seen for the pose which showed the lowest docking 385 score for each of the drug-allele combinations. 386
Discussion
387
The purpose of this study was to investigate the associations seen between HLA and anti-thyroid 388 alleles, focusing on the commonalities seen between the HLA-B associated alleles, to identify a 389 potential shared mechanism. This was done through comparing the peptide binding regions, 390
including the whole peptide binding groove and specific residue changes alongside the predicted 391 binding positions of the drugs with each of the risk and control alleles. It was found that the risk 392 alleles favour different peptides and so we can conclude that the gross structures of their peptide 393 binding grooves are rather dissimilar. However, when the multiple sequence alignments were used 394 to focus on specific residue changes, it could be seen that two residues were found to be unique to 395 the risk alleles. These two residues, Cys67 and Thr80, were therefore considered to be potentially 396 important for the mechanism of action for the adverse drug reactions seen, confirming the results of 397 a previous study by Chen et al. where the Cys67 and Thr80 were identified, amongst others, as 398 potentially important for the binding of the associated drugs with the risk alleles (18). From the 399 results of the molecular docking, the risk alleles were shown to favour the F-pocket for both drugs. 400
This pocket lies alongside the Thr80 residue which was identified as potentially important for the 401 mechanism of action. It was seen that the Thr80 interacts hydrophobically with the thiocarbonyl 402 group of both associated drugs in B*27:05, with similar interactions also being seen, but to a lesser 403 extent, with B*38:02. The residue at position 80 of the control alleles was seen to only make 404 interactions with the methimazole for B*54:01, although these were different interactions from 405 those seen for the risk alleles. For propylthiouracil, this position made interactions with the molecule 406 for three of the five control alleles, although these were again seen as different interactions to the 407 risk, with the B*38:01 possible risk showing similar interactions to the B*27:05 risk allele. It is 408 therefore reasonable to conclude that Thr80 could be involved in the mechanism of interaction, if 409 only indirectly by influencing the conformations of the surrounding residues located around the F-410 pocket. 411
Although the docking results for the risk alleles showed consistent results, with the risk alleles 412 always favouring the F-pocket, the predicted poses for the control alleles showed some variation 413 with some drug-allele combinations favouring the B-pocket and some favouring the F-pocket. 414
Docking has previously been shown to be imperfect when considering these complex HLA cases (43), 415 it is therefore understandable that the docking was unable to distinguish completely between risk 416 and control for this case. Docking results are commonly reported as the most favourable pose, here 417 we show a comparison of multiple runs as well as comparisons with selected control alleles The risk 418 alleles are shown to continuously favour the F-pocket over many runs, providing evidence that this is 419 more likely position of binding. The variation seen between controls could be due to a number of 420 factors including the homology modelling of the protein structures. As discussed in a previous study 421 (43), homology modelling can impact the docking performance and inaccurate models could result in 422 inaccurate docking results. Here, the similar alleles B*38:02 (risk) and B*38:01 (possible risk), with 423 one mutated residue at position 80, were docked with both of the associated drugs. These alleles 424 showed similar binding patterns with both alleles generally favouring the F-pocket. Since we have 425 concluded here that the Thr80 could potentially be involved in the mechanism of action, it would be 426 expected that the B*38:01 would show different docking results to the risk alleles as this allele does 427 not possess a Threonine residue at position 80. However, both the B*38:02 and B*38:01 structures 428 were obtained through homology modelling. This could impact the results of the molecular docking 429 as although the mutation has been modelled, it may not have been accurately represented here and 430 the similar structures could produce similar models. 431
The results seen here confirm and build on those seen in the Chen et al. study (18) , with Thr80 being 432 identified as important for the mechanism of the adverse drug reaction. The Chen et al. study 433 conducted docking of B*38:02, B*38:01 and DRB1*08:03 with methimazole and propylthiouracil. 434
Models were created for B*38:02 and B*38:01 using the same five templates (A*24:02, C*08:01 and 435 A*02:01 along with mouse MHC and human HLA-E) and the model for DRB1*08:03 created using 436 one template (DRB1*01:01). The templates used for the B alleles show similarities of 83-86% with 437 B*38:02 and the DRB1*01:01 template shows 92% identity with DRB1*08:03. In this study, the 438 B*38:02 model was created using templates with 95-98% identity with differing templates with 439 similar identity being used for the other modelled structures created. Model selection is a very 440 important aspect of molecular docking and can greatly impact the docking results seen (43). This 441 study was able to recreate similar docking results seen previously for B*38:02 and B*38:01, using 442 our own modelled structures, whilst also incorporating docking results for the B*27:05 risk allele and 443 comparisons with selected control alleles. Here, we also went further to investigate the structural 444 differences between the associated risk alleles and selected controls, through sequence alignments 445 and comparison of binding motifs. 446
In order to further our understandings of the mechanisms involved here and to test the hypothesis 447 that the Thr80 is important for binding, it would be interesting to investigate B*38:01 further as this 448 is a good potential biological control due to its similarity with the associated B*38:02. For this, 449 further association studies to confirm the association status of B*38:01 would be needed. Structural 450 analysis through crystal structures would be needed to confirm the binding predictions of the drug 451 allele combinations investigated and therefore the involvement of Thr80 in the predisposition to this 452 adverse drug reaction. 453 Supporting Information 571 S1 Table: Structures (17) (Han Northern China) with control frequency over 3% and alleles from the Hallberg et al. study 579 (20) with AFND frequency greater than 3% in at least one population (Sweden, France, Spain, or 580 Germany). Panels show alleles separated not only by population but also separating those alleles 581 that were selected as suitable controls. 582 Fig: Alignment of positions potentially involved in binding for the B and F pockets. Unique 588 matches identified at these positions are shown highlighted in red. 589 S4 Fig: Organisation of subsites along the HLA peptide binding groove. The six subsites along the 590 peptide biding groove (A-F) are shown highlighted (44, 45) . Image created using PyMOL (46) . 591 S14 Fig: LigPlot figures for B*27:05 show comparisons between alleles, amino-acids at positions found interacting for MMZ highlighted 640 with red circle. Hydrogen bonds shown by green dotted lines. Hydrophobic bonds shown in red. 641 S15 Fig: LigPlot figures for B*38:02 
